Prevention and treatment of amyloidogenic disease

• US 6,808,712 B2
• Filed: 03/31/2004
• Issued: 10/26/2004
• Est. Priority Date: 12/02/1997
• Status: Expired due to Term

• Current Assignee: Janssen Alzheimer Immunotherapy (Johnson & Johnson), Elan Pharmaceuticals Incorporated (Perrigo Company PLC)
• Original Assignee: Neuralab Ltd. (Perrigo Company PLC)
• Inventors: Schenk, Dale B.
• Primary Examiner(s): SCHEINER, LAURIE A
• Application Number:
  US10/815,353
• Publication Number:
  US 20040170641A1
• Time in Patent Office: 209 Days
• Field of Search: 424/185.1, 424/193.1, 530/300, 530/327, 530/329, 530/330, 530/350, 530/391.7, 530/403, 514/2, 514/4
• US Class Current: 424/193.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/55505 Inorganic adjuvants
• CPC Class Codes: A61K 2039/55555 Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 2039/55572 Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
• CPC Class Codes: A61K 2039/55577 Saponins; Quil A; QS21; ISCOMS
• CPC Class Codes: A61K 2039/6037 Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
• CPC Class Codes: A61K 2039/605 MHC molecules or ligands thereof
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/739 Lipopolysaccharides
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0007 Nervous system antigens; Prions
• CPC Class Codes: A61K 47/646 the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/2009 Inorganic compounds
• CPC Class Codes: A61K 9/2031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
• CPC Class Codes: A61K 9/2054 : Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/4866 : Organic macromolecular compounds
• CPC Class Codes: A61K 9/7023 : Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: A61P 25/00 : Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 : for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 37/00 : Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/4711 : Alzheimer's disease; Amyloid plaque core protein
• CPC Class Codes: C07K 16/18 : against material from animals or humans
• CPC Class Codes: C07K 2317/24 : containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/567 : Framework region [FR]
• CPC Class Codes: C07K 2319/00 : Fusion polypeptide

Abstract

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response an amyloid deposit in the patient. The methods are particularly useful for prophylatic and therapeutic treatment of Alzheimer'"'"'s disease. In such methods, a suitable agent is Aβ peptide or an antibody thereto.

Claims

1. A pharmaceutical composition comprising an immunogenic Aβ

fragment linked to an immunoglobulin carrier molecule to form a conjugate and an adjuvant, wherein the adjuvant enhances an immune response comprising antibodies to the Aβ

fragment.

2. The pharmaceutical composition of claim 1, wherein the Aβ

fragment is from the N-terminal half of Aβ

.

3. The pharmaceutical composition of claim 2, wherein the Aβ

fragment is Aβ

1-5.

4. The pharmaceutical composition of claim 3, wherein Aβ

1-5 consists of the first five N-terminal amino acids of SEQ ID NO;

1.

5. The pharmaceutical composition of claim 2, wherein the Aβ

fragment is Aβ

1-6.

6. The pharmaceutical composition of claim 5, wherein Aβ

1-6 consists of the first six N-terminal amino acids of SEQ ID NO;

1.

7. The pharmaceutical composition of claim 2, wherein the Aβ

fragment is Aβ

1-12.

8. The pharmaceutical composition of claim 7, wherein Aβ

1-12 consists of the first 12 N-terminal amino acids of SEQ D NO;

1.

9. The pharmaceutical composition of any one of claims 1-8, wherein the adjuvant comprises alum.

10. The pharmaceutical composition of any one of claims 1-8, wherein the adjuvant comprises monophosphoryl lipid (MPL).

11. The pharmaceutical composition of any one of claims 1-8, wherein the adjuvant comprises Quillaja Saponaria Molina (QS21).

12. The pharmaceutical composition of any one of claims 1-8, wherein the adjuvant comprises GM-CSF.

13. The pharmaceutical composition of any one of claims 1-8, wherein the adjuvant comprises M-CSF.

14. The pharmaceutical composition of any one of claims 1-8, which comprises greater than 10 μ

g of the Aβ

fragment.

15. The pharmaceutical composition of any one of claims 1-8, which comprises at least 50 μ

g of the Aβ

fragment.

16. The pharmaceutical composition of any one of claims 1-8, which comprises at least 50 μ

g of the Aβ

fragment.

17. The pharmaceutical composition of any one of claims 1-8, which comprises at least 100 μ

g of the Aβ

fragment.

18. The pharmaceutical composition of claim 1, wherein the adjuvant is selected from the group consisting of alum, monophosphoryl lipid (MPL), Quillaja Saponaria Molina (QS21), GM-CSF, and M-CSF.

19. The pharmaceutical composition of claim 18, which comprises greater than 10 μ

g of the Aβ

fragment.

20. The pharmaceutical composition of claim 18, which comprises at least 20 μ

g of the Aβ

fragment.

21. The pharmaceutical composition of claim 18, which comprises at least 50 μ

g of the Aβ

fragment.

22. The pharmaceutical composition of claim 18, which comprises at least 100 μ

g of the Aβ

fragment.

23. The pharmaceutical composition of claim 18, wherein the Aβ

fragment is from the N-terminal half of Aβ

.

24. The pharmaceutical composition of claim 23, wherein the Aβ

fragment is Aβ

1-5.

25. The pharmaceutical composition of claim 24, wherein Aβ

1-5 consists of the first five N-terminal amino acids of SEQ ID NO;

1.

26. The pharmaceutical composition of claim 23, wherein the Aβ

fragment is Aβ

1-6.

27. The pharmaceutical composition of claim 26, wherein Aβ

1-6 consists of the first six N-terminal amino acids of SEQ ID NO;

1.

28. The pharmaceutical composition of claim 23, wherein the Aβ

fragment is Aβ

1-12.

29. The pharmaceutical composition of claim 28, wherein Aβ

1-12 consists of the first 12 N-terminal amino acids of SEQ ID NO;

1.